Compass Biomedical

Compass Biomedical is a biotechnology company specializing in the development and commercialization of platelet-derived products and cell culture solutions for regenerative medicine. Originally the research and development division of Arteriocyte, the company rebranded in 2016 following the sale of its orthopedic division to Isto Biologics. Its flagship product, PLUS™ Human Platelet Lysate, is a clinical-grade, xeno-free alternative to fetal bovine serum used for the rapid expansion of human cells such as mesenchymal stem cells and T cells. The company also utilizes its proprietary NANEX™ platform, a nanofiber-based technology that mimics the bone marrow environment to facilitate the expansion of hematopoietic stem cells. Compass Biomedical provides contract research and manufacturing services (CRAMS) to support partners in transitioning cell-based therapies from the laboratory to clinical applications. The company maintains a Type II Drug Master File with the FDA for its PLUS™ product, ensuring high regulatory standards for its clinical-grade offerings.